Healthy Extracts (OTCQB: HYEX), a leading developer and manufacturer of heart health, brain health and supplementary technologies, has announced its year-end financial numbers and business updates for the 12-month period ending Dec. 31, 2020. Financial highlights of the report include revenue increases of 71% to $1,276,559 compared to 2019 revenues of $748,377 and a net shareholder equity increase of $3.7 million. In addition, the company eliminated all convertible debt. The report attributes the increases to Healthy Extracts transition to its new business of selling health-nutrition products. Business highlights for the year include a company name change, full reporting and upgrade to the OTCQB, the acquisition of Ultimate Brain Nutrients and the introduction of two key products: Clinical Immune and HerHeart. In addition, the company reported key progress on clinical studies and pilot studies focusing on its proprietary Fuel4Thought Brain Booster product, which is slated for release in Q2. “I am extremely excited about 2021 and our Live Life Young Again strategy,” said Healthy Extracts president Duke Pitts in the press release. “Our name and ticker symbol changes were finalized last week, transitioning to Healthy Extracts Inc., which aligns us with our corporate objectives. Our 2020 results demonstrate continued momentum for the company.”
To view the full press release, visit https://ibn.fm/gbaof
About Healthy Extracts Inc.
Healthy Extracts through its two subsidiaries, BergaMet NA and Ultimate Brain Nutrients (“UBN”), is engaged in proprietary research and development of natural plant-based formulations, as well as sales and distribution of natural-ingredient cardiovascular and neuro products. For more information about the company, please visit www.HealthyExtractsInc.com.
NOTE TO INVESTORS: The latest news and updates relating to HYEX are available in the company’s newsroom at https://ibn.fm/HYEX
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
Nutriband (NASDAQ: NTRB) has released a shareholder letter from CEO Gareth Sheridan outlining key achievements…
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, is advancing its phase 3 replication study (“FLASH2”)…
Adageis is revolutionizing healthcare with its flexible, AI-centric software solutions and ProActive Care Platform, built to…
HeartBeam (NASDAQ: BEAT) announced that its synthesized 12-lead ECG technology met clinical endpoints in the VALID-ECG…
NextPlat (NASDAQ: NXPL, NXPLW) announced it has received a written notice from Nasdaq Stock Market LLC…
Calidi Biotherapeutics (NYSE American: CLDI) announced the selection of IL15 superagonist (IL15-IL15Ra) as the first…